WO2001068586A3 - α4β1 AND α4β7 INTEGRIN INHIBITORS - Google Patents
α4β1 AND α4β7 INTEGRIN INHIBITORS Download PDFInfo
- Publication number
- WO2001068586A3 WO2001068586A3 PCT/EP2001/002749 EP0102749W WO0168586A3 WO 2001068586 A3 WO2001068586 A3 WO 2001068586A3 EP 0102749 W EP0102749 W EP 0102749W WO 0168586 A3 WO0168586 A3 WO 0168586A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- integrin inhibitors
- inhibitors
- integrins
- inflammatory
- therapeutic
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001262089A AU2001262089A1 (en) | 2000-03-14 | 2001-03-12 | Alpha4beta1 and alpha4beta7 integrin inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52570000A | 2000-03-14 | 2000-03-14 | |
US09/525,700 | 2000-03-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001068586A2 WO2001068586A2 (en) | 2001-09-20 |
WO2001068586A3 true WO2001068586A3 (en) | 2002-01-10 |
Family
ID=24094284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/002749 WO2001068586A2 (en) | 2000-03-14 | 2001-03-12 | α4β1 AND α4β7 INTEGRIN INHIBITORS |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001262089A1 (en) |
WO (1) | WO2001068586A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL374971A1 (en) | 2002-08-09 | 2005-11-14 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
US7015323B2 (en) | 2003-05-20 | 2006-03-21 | Genentech, Inc. | Thiocarbamate inhibitors of alpha-4 integrins |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
CA2531796A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
ATE549321T1 (en) | 2006-11-22 | 2012-03-15 | Ajinomoto Kk | METHOD FOR THE PRODUCTION OF PHENYLALANINE DERIVATIVES WITH CHINAZOLINDIONE STANDARDS, AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION |
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
HRP20211911T1 (en) | 2013-03-15 | 2022-03-18 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses therof |
US20140294902A1 (en) * | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
SI3143037T1 (en) | 2014-05-16 | 2021-11-30 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
CA2955460A1 (en) | 2014-07-17 | 2016-01-21 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
WO2017165676A1 (en) | 2016-03-23 | 2017-09-28 | Protagonist Therapeutics, Inc. | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP4233902A3 (en) | 2016-12-14 | 2024-02-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
CA3073806A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
EP3873884A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
JP7189368B2 (en) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | Compounds for inhibition of alpha4beta7 integrin |
KR102641718B1 (en) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
KR20210095165A (en) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | Methods and devices for treating diseases with biopharmaceuticals |
CA3146390A1 (en) | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
KR20220047323A (en) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Compounds for Inhibiting Alpha 4 Beta 7 Integrin |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP4090670A1 (en) | 2020-01-15 | 2022-11-23 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CA3202226A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053814A1 (en) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
WO1999006437A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals Inc. | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO1999035163A1 (en) * | 1998-01-08 | 1999-07-15 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO1999037618A1 (en) * | 1998-01-27 | 1999-07-29 | Celltech Therapeutics Limited | Phenylalanine derivatives useful as pharmaceutical agents |
WO1999043642A1 (en) * | 1998-02-26 | 1999-09-02 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
WO1999067230A1 (en) * | 1998-06-23 | 1999-12-29 | Pharmacia & Upjohn Company | INHIBITORS OF α4β1 MEDIATED CELL ADHESION |
-
2001
- 2001-03-12 WO PCT/EP2001/002749 patent/WO2001068586A2/en active Application Filing
- 2001-03-12 AU AU2001262089A patent/AU2001262089A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053814A1 (en) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
WO1999006437A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals Inc. | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO1999035163A1 (en) * | 1998-01-08 | 1999-07-15 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO1999037618A1 (en) * | 1998-01-27 | 1999-07-29 | Celltech Therapeutics Limited | Phenylalanine derivatives useful as pharmaceutical agents |
WO1999043642A1 (en) * | 1998-02-26 | 1999-09-02 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
WO1999067230A1 (en) * | 1998-06-23 | 1999-12-29 | Pharmacia & Upjohn Company | INHIBITORS OF α4β1 MEDIATED CELL ADHESION |
Non-Patent Citations (4)
Title |
---|
DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FOEDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002180175 * |
DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FOEDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002180176 * |
PHARMAZIE, vol. 38, no. 3, 1983, pages 170 - 171 * |
YAKUGAKU ZASSHI, vol. 74, 1954, pages 1287 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001262089A1 (en) | 2001-09-24 |
WO2001068586A2 (en) | 2001-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001068586A3 (en) | α4β1 AND α4β7 INTEGRIN INHIBITORS | |
MXPA04001889A (en) | Alkyne-aryl phosphodiesterase-4 inhibitors. | |
EE200200710A (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
WO2002060894A3 (en) | Sulfonamide lactam inhibitors of factor xa | |
WO2003050087A3 (en) | Novel herbicides | |
IL152916A0 (en) | Heteroaryl-phenyl heterobicyclic factor xa inhibitors | |
FR2835186B1 (en) | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS | |
MY127126A (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | |
EP1864665A4 (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
DE60005355D1 (en) | BRADIKININ B1 RECEPTOR ANTAGONISTS | |
WO2002099388A3 (en) | Benzodiazepine bradykinin antagonists | |
DE60205899D1 (en) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
PL374259A1 (en) | Novel heterocyclic compounds as selective bacterial dhfr inhibitors and their uses thereof | |
ITTO20040125A1 (en) | NEW HETEROCYCLIC AMIDINS INHIBITIVE THE PRODUCTION OF NITROGEN OXIDE (NO) FOR ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY | |
WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
DK1109810T3 (en) | Benzonaphthydine N-oxides with PDE3 and PDE4 inhibitory activity | |
BR9907733A (en) | Antagonists vla-4 | |
WO1999026932A8 (en) | By amidino group substituted heterocyclic derivatives and their use as anticoagulants | |
WO2001030782A3 (en) | Novel herbicides | |
WO2004058712A3 (en) | Herbicidally active nicotinoyl derivates | |
WO2004041827A3 (en) | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α] IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE AND THEIR USE AS INHIBITORS UPON THE INTERACTION OF CAMS AND LEUKO INTEGRINS | |
FR2844273B1 (en) | NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS. | |
ATE277023T1 (en) | INDANDERIVATES AND THEIR USE AS CELL ADHESION INHIBITORS | |
TWI255813B (en) | Compounds for use as alphavbeta3 receptor antagonists | |
WO2001046128A3 (en) | Tryptase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |